
DexCom, Inc.

DXCM (DexCom, Inc.) trades at 5.1x EV/Revenue — reasonably priced for a biotech & healthcare company with strong gross margins (60%) and mature growth profile. The business is profitable at 25% EBIT margins. Forward PE of 27x.
The S&P 500 has returned an average of 10.7% annually since 1926 — but only 6 of those years actually returned between 8-12%.
Gold Eagle provides data and AI-generated analysis for informational purposes only. Not investment advice. All data from public sources.
DexCom develops and manufactures continuous glucose monitoring (CGM) systems that help people with diabetes track their blood sugar levels in real-time without finger pricks. Their flagship G7 and G6 devices provide glucose readings every minute to smartphones and other devices, serving over 2 million users globally. They generate revenue primarily through device sales and recurring sensor subscriptions, creating a razor-and-blade business model.
DexCom has delivered 20%+ annual revenue growth driven by geographic expansion internationally and penetration into the much larger Type 2 diabetes market. The global CGM market is projected to grow at 8-12% annually through 2030, with DexCom positioned to capture outsized share through its premium technology platform. Key growth catalyst is the ongoing shift from traditional blood glucose monitoring to continuous monitoring across all diabetes types.
The company maintains strong gross margins around 65-70% due to its premium positioning and proprietary sensor technology. Operating leverage is improving as the business scales, with expanding international operations and growing sensor volumes driving margin expansion. DexCom generates strong free cash flow and has achieved consistent GAAP profitability, reinvesting heavily in R&D and international expansion.
DexCom holds the #2 position globally behind Abbott's FreeStyle Libre but leads in the premium/high-accuracy segment. Their integrated ecosystem approach, superior mobile app experience, and clinical-grade accuracy differentiate them from lower-cost alternatives. The company maintains strong relationships with endocrinologists and diabetes educators, creating switching costs and brand loyalty.
Without access to recent quarterly results, DexCom has historically shown consistent beat-and-raise patterns driven by better-than-expected user growth and international expansion. The company typically sees seasonal strength in Q4 due to insurance deductible resets and new patient additions. Market sentiment generally tracks user growth metrics and international revenue progression.
Analysts typically maintain bullish long-term views on DexCom given the large addressable market and recurring revenue model, though debate centers on competitive positioning versus Abbott and pace of Type 2 diabetes market penetration. Consensus expectations usually focus on user growth rates, international expansion progress, and margin expansion trajectory.
DexCom is the premium player in the fast-growing continuous glucose monitoring market with a razor-blade business model, positioned to benefit from the massive shift away from traditional finger-stick testing across all diabetes types.








| '25E | '26E | '27E | '28E | |
|---|---|---|---|---|
| Revenue | — | $5.2B | $5.9B | $6.6B |
| Growth | — | +12% | +12% | |
| EBITDA | — | $1.8B | $2.1B | $2.3B |
| Growth | — | +12% | +12% | |
| EPS (PF) | — | $2.49 | $2.99 | $3.57 |
| Growth | — |
Touchstone Sands Capital Select Growth Fund Q4 2025 Portfolio Review
Dexcom Showcases Breakthrough Outcomes for People With Type 2 Diabetes and Product Roadmap at ATTD 2026
DexCom: Gaining Favor, With Useful Tailwinds To Support It Even Further
DexCom, Inc. (DXCM) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
Dexcom Appoints Rick Osterloh to Board of Directors
| +20% |
| +19% |